- Home
- ASIX vs XERS Comparison
ASIX vs XERS Comparison
Compare ASIX & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASIX
- XERS
- Stock Information
- Founded
- ASIX 2016
- XERS 2005
- Country
- ASIX United States
- XERS United States
- Employees
- ASIX N/A
- XERS N/A
- Industry
- ASIX Major Chemicals
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- ASIX Industrials
- XERS Health Care
- Exchange
- ASIX Nasdaq
- XERS Nasdaq
- Market Cap
- ASIX 654.2M
- XERS 752.7M
- IPO Year
- ASIX N/A
- XERS 2018
- Fundamental
- Price
- ASIX $23.12
- XERS $5.11
- Analyst Decision
- ASIX Buy
- XERS Strong Buy
- Analyst Count
- ASIX 1
- XERS 6
- Target Price
- ASIX $32.00
- XERS $6.25
- AVG Volume (30 Days)
- ASIX 180.9K
- XERS 2.0M
- Earning Date
- ASIX 08-01-2025
- XERS 08-07-2025
- Dividend Yield
- ASIX 2.77%
- XERS N/A
- EPS Growth
- ASIX 3682.26
- XERS N/A
- EPS
- ASIX 3.11
- XERS N/A
- Revenue
- ASIX $1,558,519,000.00
- XERS $222,551,000.00
- Revenue This Year
- ASIX $7.41
- XERS $35.03
- Revenue Next Year
- ASIX $4.60
- XERS $18.31
- P/E Ratio
- ASIX $7.57
- XERS N/A
- Revenue Growth
- ASIX 6.03
- XERS 29.88
- 52 Week Low
- ASIX $18.44
- XERS $2.10
- 52 Week High
- ASIX $33.00
- XERS $6.07
- Technical
- Relative Strength Index (RSI)
- ASIX 41.77
- XERS 61.48
- Support Level
- ASIX $24.37
- XERS $4.62
- Resistance Level
- ASIX $25.53
- XERS $5.39
- Average True Range (ATR)
- ASIX 0.70
- XERS 0.21
- MACD
- ASIX -0.12
- XERS 0.07
- Stochastic Oscillator
- ASIX 17.18
- XERS 71.72
About ASIX AdvanSix Inc.
AdvanSix Inc. is a diversified chemistry company playing a critical role in globally supply chains, innovating and delivering essential products for customers in a wide variety of end markets and applications that touch people's lives, such as building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives and electronics. The company key products includes: Nylon, Caprolactam, Plant Nutrients, and Chemical Intermediates The majority of sales is from Plant Nutrients products.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).